Moffitt research of Selinexor for multiple myeloma facilitates FDA approval

(H. Lee Moffitt Cancer Center& Research Institute) A first-in-class drug recently granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with heavily pretreated multiple myeloma has been the subject of study at Moffitt Cancer Center for years. Now, selinexor (XPOVIO ™ , Karyopharm Therapeutics) used in combination with the corticosteroid dexamethasone will offer another option for patients with multiple myeloma who have exhausted the most common therapies for the disease.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news